

ORIGINAL ARTICLE

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, M.D., Robert Croop, M.D., Elyse G. Stock, M.D., David A. Stock, Ph.D., Beth A. Morris, B.A., Marianne Frost, M.A., Gene M. Dubowchik, Ph.D., Charles M. Conway, Ph.D., Vladimir Coric, M.D., and Peter J. Goadsby, M.D., Ph.D.

ABSTRACT

BACKGROUND

Calcitonin gene–related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene–related peptide receptor antagonist that may be effective in acute migraine treatment.

METHODS

In a multicenter, double-blind, phase 3 trial, we randomly assigned adults with at least a 1-year history of migraine and two to eight migraine attacks of moderate or severe intensity per month to receive rimegepant orally at a dose of 75 mg or matching placebo for the treatment of a single migraine attack. The primary end points were freedom from pain and freedom from the most bothersome symptom (other than pain) identified by the patient, both of which were assessed 2 hours after the dose of rimegepant or placebo was administered.

RESULTS

A total of 1186 patients were randomly assigned to receive rimegepant (594 patients) or placebo (592 patients); of these, 537 patients in the rimegepant group and 535 patients in the placebo group could be evaluated for efficacy. The overall mean age of the patients evaluated for efficacy was 40.6 years, and 88.7% were women. In a modified intention-to-treat analysis, the percentage of patients who were pain-free 2 hours after receiving the dose was 19.6% in the rimegepant group and 12.0% in the placebo group (absolute difference, 7.6 percentage points; 95% confidence interval [CI], 3.3 to 11.9; $P < 0.001$). The percentage of patients who were free from their most bothersome symptom 2 hours after the dose was 37.6% in the rimegepant group and 25.2% in the placebo group (absolute difference, 12.4 percentage points; 95% CI, 6.9 to 17.9; $P < 0.001$). The most common adverse events were nausea and urinary tract infection.

CONCLUSIONS

Treatment of a migraine attack with the oral calcitonin gene–related peptide receptor antagonist rimegepant resulted in a higher percentage of patients who were free of pain and free from their most bothersome symptom than placebo. (Funded by Biohaven Pharmaceuticals; ClinicalTrials.gov number, NCT03237845.)

From the Departments of Neurology and Epidemiology and Population Health, Albert Einstein College of Medicine, and Montefiore Medical Center — both in Bronx, NY (R.B.L.); Biohaven Pharmaceuticals, New Haven, CT (R.C., E.G.S., D.A.S., B.A.M., M.F., G.M.D., C.M.C., V.C.); NIHR–Wellcome Trust King's Clinical Research Facility, King's College Hospital–South London and Maudsley Biomedical Research Centre, King's College London, London (P.J.G.); and the University of California, San Francisco, San Francisco (P.J.G.). Address reprint requests to Dr. Lipton at Montefiore Medical Center, Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, 1165 Morris Park Ave., Bronx, NY 10461, or at richard.lipton@einstein.yu.edu.

A list of investigators in this trial is provided in the Supplementary Appendix, available at NEJM.org.

N Engl J Med 2019;381:142-9.

DOI: 10.1056/NEJMoa1811090

Copyright © 2019 Massachusetts Medical Society.

MIGRAINE IS A COMMON CHRONIC neurologic disease that may affect nearly 1 billion people worldwide.¹ Serotonin 5-HT_{1B} and 5-HT_{1D} receptor agonists (triptans) have been the most widely prescribed acute migraine treatments for decades. However, some patients who use triptans either do not have a response (34%)² or have recurrences of attacks (30 to 40%)³⁻⁵; in addition, up to 52% have adverse effects from triptans,⁶ and concerns about these effects were reported in one study to result in delays in treatment or avoidance of treatment in two thirds of patients.⁷ Triptans also are either contraindicated or must be used with caution in an estimated 3.5 million of the 40 million Americans with migraine because of concerns about cardiovascular effects.^{8,9}

Calcitonin gene-related peptide (CGRP) plays a role in the pathophysiological features of migraine,¹⁰⁻¹² and small-molecule CGRP receptor antagonists (gepants) have been shown to be effective in acute migraine treatment in several previous trials.¹³⁻¹⁷ Gepants may be effective in patients whose symptoms do not respond to triptans, owing to their different mechanisms of action. Unlike triptans, which are contraindicated in patients with cardiovascular disease because of the possibility of vasoconstriction, rimegepant does not have vasoconstrictive effects.¹⁶

In a previous randomized, double-blind, placebo-controlled, dose-ranging, phase 2b trial that evaluated multiple oral dose levels of rimegepant, the 75-mg dose was superior to placebo with respect to the elimination of pain, nausea, photophobia, and phonophobia 2 hours after administration of the dose and had sustained effects through 24 and 48 hours.¹⁶ The current phase 3 trial was conducted to evaluate the efficacy and safety of rimegepant (at an oral dose of 75 mg), as compared with placebo, in acute migraine treatment.

METHODS

TRIAL POPULATION

Men and women 18 years of age or older were recruited by referral from physicians and other health care professionals and by standard methods of recruitment, including enrollment from clinical practices and through advertising. Treatment settings included clinics, institutions, and private office practices. Eligible participants had

migraine, with or without aura, that met the criteria specified in the *International Classification of Headache Disorders, 3rd edition (beta version)*¹⁸; had a 1-year history of migraine, with an onset before the age of 50 years; had two to eight migraine attacks of moderate or severe intensity per month; and had any headache on fewer than 15 days per month during the previous 3 months. Persons who were receiving preventive migraine medication had to be receiving a stable dose for at least 3 months before trial entry.

A key exclusion criterion was a history of any clinically significant or unstable medical condition, including alcohol or drug abuse and substance-use disorder, that would expose patients to an undue risk of an adverse event or that could interfere with assessments of safety or efficacy. Patients were also excluded if they had received nonbiologic investigational agents within 30 days before the baseline visit or if they had received biologic investigational agents within 90 days before the baseline visit. Complete criteria for participation are listed in the protocol, available with the full text of this article at NEJM.org.

TRIAL OVERSIGHT

The trial was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable local regulations. The protocol was approved by an independent ethics committee or institutional review board at each trial center. All patients provided written informed consent. Biohaven Pharmaceuticals sponsored the trial, supplied the trial agents, reviewed the trial design, collected the data, and performed data management and analysis. The manuscript was written with the assistance of a medical writer funded by Biohaven Pharmaceuticals. All the authors have confidentiality agreements with Biohaven Pharmaceuticals, either as a condition of employment or in their role as consultants. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol.

TRIAL DESIGN

In this multicenter, randomized, double-blind, phase 3 trial, we evaluated the safety and efficacy of rimegepant at an oral dose of 75 mg, as compared with placebo, for acute migraine treat-




Figure 1. Enrollment, Randomization, and Follow-up.

ment. After providing written informed consent, patients underwent screening procedures as specified in the protocol. Patients returned to the trial centers within 3 to 28 days after screening and were randomly assigned, in a 1:1 ratio, to the rimegepant group or the placebo group with the use of an interactive Web-response system. They were given an electronic diary and were instructed on the proper use of the diary before they left the trial center.

Patients were provided with one 75-mg dose of rimegepant or matching placebo and were instructed to take the tablet when a single migraine attack of moderate or severe intensity occurred. Before taking the tablet, they answered questions in the electronic diary about their current pain and symptoms, and they identified and recorded their current most bothersome migraine-associated symptom, other than pain (i.e., phonophobia, photophobia, or nausea). Patients completed the electronic diary for up to 48 hours after taking the trial agent. Pain intensity, the presence or absence of associated symptoms, and ratings of functional disability were assessed at the onset of the treated attack; at 15, 30, 45, 60, and 90 minutes after the dose; and at 2, 3, 4, 6, 8, 24, and 48 hours after the dose.

Patients were asked to return to the trial center within 7 days after taking the dose of rimegepant or placebo. At that visit, trial personnel reviewed adherence to the electronic diary assessments, confirmed that the patient had taken the dose, and monitored safety variables. Patients who had not had an attack of sufficient severity within 45 days after randomization were withdrawn and were instructed to return the unused trial agent and the electronic diary.

END POINTS

The primary efficacy end points were freedom from pain (which was defined by the presence of no pain in a person who had had pain of moderate or severe intensity immediately before administration of the dose) and freedom from the patient's most bothersome symptom associated with migraine (i.e., phonophobia, photophobia, or nausea), 2 hours after the dose. Secondary end points were freedom from photophobia and from phonophobia, pain relief (which was defined by the presence of mild pain or no pain in a patient who had had pain of moderate or severe intensity immediately before administration of the dose), and freedom from nausea, each assessed 2 hours after the dose of rimegepant or placebo; the probability of using rescue medication within 24 hours after the dose; sustained freedom from pain and sustained pain relief from 2 hours to 24 hours after the dose; sustained freedom from pain and sustained pain relief from 2 hours to 48 hours after the dose; pain relapse (which was defined by the return of headache pain of any intensity after being pain-free 2 hours after the dose) from 2 hours to 48 hours after the dose;

Table 1. Characteristics of the Modified Intention-to-Treat Population.*

Characteristic	Rimegepant (N = 537)	Placebo (N = 535)	Total (N = 1072)
Age — yr	40.2±11.9	40.9±12.1	40.6±12.0
Female sex — no. (%)	479 (89.2)	472 (88.2)	951 (88.7)
Race or ethnic group — no. (%)†			
White	394 (73.4)	399 (74.6)	793 (74.0)
Black	111 (20.7)	118 (22.1)	229 (21.4)
Asian	8 (1.5)	8 (1.5)	16 (1.5)
Native Hawaiian or Other Pacific Islander	6 (1.1)	0	6 (0.6)
American Indian or Alaska Native	4 (0.7)	5 (0.9)	9 (0.8)
Multiple	14 (2.6)	5 (0.9)	19 (1.8)
Hispanic ethnic group — no. (%)‡	77 (14.3)	83 (15.5)	160 (14.9)
Body-mass index‡	31.0±7.9	31.8±8.5	31.4±8.2
Migraine history			
Attacks per month — no.	4.5±1.9	4.6±1.8	4.6±1.8
Average duration of untreated attacks — hr	32.0±22.5	32.9±21.7	32.5±22.1
Most bothersome symptom — no. (%)			
Photophobia	277 (51.6)	279 (52.1)	556 (51.9)
Phonophobia	72 (13.4)	92 (17.2)	164 (15.3)
Nausea	169 (31.5)	148 (27.7)	317 (29.6)
Missing data§	19 (3.5)	16 (3.0)	35 (3.3)

* Plus–minus values are means ±SD. The modified intention-to-treat population included patients who underwent randomization, had a migraine attack with pain of moderate or severe intensity, took a dose of rimegepant or placebo, and had at least one efficacy assessment after administration of the dose. There were no significant between-group differences at baseline for any characteristic. Percentages may not total 100 because of rounding.

† Race and ethnic group were reported by the patient.

‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.

§ In the analysis of the most bothersome symptom, patients with missing data were considered to have treatment failure.

and the ability to function at a normal level 2 hours after the dose. The methods used to measure efficacy end points are described in the Supplementary Appendix, available at NEJM.org. Safety and other assessments included evaluation of adverse events, electrocardiography, vital signs, measurements of height and weight, routine laboratory testing and the Sheehan Suicidality Tracking Scale.¹⁹

STATISTICAL ANALYSIS

We estimated that approximately 90% of the 600 patients randomly assigned to each treatment group would have a migraine attack that met the protocol-specified criteria in the allotted time period, which would result in approximately 550 patients in each group who would receive rimegepant or placebo. On the basis of the results of the previous phase 2b trial,¹⁶ we estimated that a sample of 550 patients in each group

would provide the trial with more than 95% power to detect a significant difference between the rimegepant group and the placebo group in each of the two primary end points and hence at least 90% power to detect a significant difference between the groups in both end points jointly. The efficacy analyses were conducted in the modified intention-to-treat population, which included all patients who underwent randomization, had a migraine attack with pain of moderate or severe intensity, took a dose of rimegepant or placebo, and had at least one efficacy assessment after administration of the dose. The safety analyses were conducted in the safety population, which included all patients who underwent randomization and took a dose of rimegepant or placebo.

We specified that rimegepant would be considered to be superior to placebo with respect to the two primary end points (freedom from pain

Table 2. Primary and Secondary End Points in the Modified Intention-to-Treat Population.*

End Point	Rimegepant (N=537)	Placebo (N=535)	Absolute Difference percentage points (95% CI)	P Value
	no./total no. (%) [†]			
Primary end points				
Freedom from pain 2 hours after the dose	105 (19.6)	64 (12.0)	7.6 (3.3 to 11.9)	<0.001
Freedom from the most bothersome symptom 2 hours after the dose	202 (37.6)	135 (25.2)	12.4 (6.9 to 17.9)	<0.001
Secondary end points				
Freedom from photophobia 2 hours after the dose	183/489 (37.4)	106/477 (22.3)	15.1 (9.4 to 20.8)	<0.001
Freedom from phonophobia 2 hours after the dose	133/362 (36.7)	100/374 (26.8)	9.9 (3.2 to 16.6)	0.004
Pain relief 2 hours after the dose	312 (58.1)	229 (42.8)	15.3 (9.4 to 21.2)	<0.001
Freedom from nausea 2 hours after the dose	171/355 (48.1)	145/336 (43.3)	4.8 (-2.7 to 12.2)	
Use of rescue medication within 24 hr after the dose	113 (21.0)	198 (37.0)	-16.0 (-21.3 to -10.6)	
Sustained freedom from pain 2 to 24 hr after the dose	66 (12.3)	38 (7.1)	5.2 (1.7 to 8.7)	
Sustained pain relief 2 to 24 hr after the dose	229 (42.6)	142 (26.5)	16.1 (10.5 to 21.7)	
Sustained freedom from pain 2 to 48 hr after the dose	53 (9.9)	32 (6.0)	3.9 (0.7 to 7.1)	
Sustained pain relief 2 to 48 hr after the dose	195 (36.3)	121 (22.6)	13.7 (8.3 to 19.1)	
Pain relapse 2 to 48 hr after the dose	52/105 (49.6)	32/64 (50.0)	-0.4 (-15.8 to 15.1)	
Ability to function normally 2 hr after the dose	175 (32.6)	125 (23.4)	9.2 (3.9 to 14.6)	

* The modified intention-to-treat population included patients who underwent randomization, had a migraine attack with pain of moderate or severe intensity, took a dose of rimegepant or placebo, and had at least one efficacy assessment after administration of the dose. To maintain the type I statistical error rate at 0.05, a prespecified hierarchical testing procedure was applied; end points are presented in the sequence in which they were evaluated. Because the incidence of freedom from nausea did not differ significantly between the groups, all statistical tests below this end point in the hierarchy are reported without P values, and no inferences can be made from those results. Percentages, absolute differences, and confidence intervals were calculated with the use of the Cochran–Mantel–Haenszel method.

[†] Percentages are Cochran–Mantel–Haenszel estimates. Total numbers are shown only when the analysis was performed in a subgroup of the modified intention-to-treat population. Photophobia, phonophobia, and nausea were evaluated only in patients in whom the symptom was present before treatment of the migraine attack, and pain relapse was evaluated only in patients who were pain-free at 2 hours.

2 hours after the dose and freedom from the most bothersome symptom 2 hours after the dose) if the P value for both comparisons was less than 0.05. These analyses were performed with the use of Cochran–Mantel–Haenszel tests, stratified according to the use of preventive migraine medication (yes vs. no); patients with missing data at the 2-hour time point after the dose was administered were considered to have treatment failure. Patients who used rescue medication were considered to have treatment failure as of the time the medications were used. We performed sensitivity analyses that took missing data into account; the results are shown in the Supplementary Appendix.

To maintain the type I error rate at 0.05, a prespecified hierarchical gatekeeping procedure was applied in which the secondary end points were tested in the order indicated above and in the protocol. A comparison was considered to be significant if that comparison and each of the

preceding comparisons showed a significant difference between the treatment groups. If a significant difference was not observed for an end point, any subsequent comparisons were reported without P values.

The probability of freedom from pain and of freedom from the most bothersome symptom over the course of 8 hours after the dose was administered was estimated with the use of the Kaplan–Meier method in exploratory time-to-event analyses. For each time point, the number of patients eligible to become free from pain or free from their most bothersome symptom and the number of patients who reported the first occurrence of the event were used to calculate the probability estimate (with 95% confidence intervals). Data from patients whose pain or most bothersome symptom persisted for 495 minutes (8 hours plus a 15-minute margin for error) were censored at 495 minutes after the dose, and data from patients who used rescue medication were

censored at the time of the dose of rescue medication. The probability estimates shown in the Kaplan–Meier plots represent the probability of a first report of freedom from pain or freedom from the most bothersome symptom.

RESULTS

PATIENTS

From July 2017 through January 2018, a total of 1186 patients participated in the trial at 49 centers in the United States. Patients were randomly assigned to receive rimegepant (594 patients) or placebo (592 patients). A total of 1086 patients received the assigned dose of rimegepant or placebo, and 1080 of these patients (99.4%) completed the trial (538 in the rimegepant group and 542 in the placebo group) (Fig. 1). The demographic and clinical characteristics of the two treatment groups were similar (Table 1). Most of the patients (88.7%) were women, and the mean age of the overall population was 40.6 years. The patients reported a history of 4.6 migraine attacks per month, each of which lasted an average of 32.5 hours if left untreated. Among the 1072 patients in the modified intention-to-treat population, of whom 734 had migraine without aura and 338 had migraine with aura, the most bothersome symptom other than pain was photophobia in 51.9%, nausea in 29.6%, and phonophobia in 15.3%. The groups were balanced with respect to the distribution of the most bothersome symptom (Table 1).

EFFICACY

Two hours after the dose of rimegepant or placebo, 19.6% of the patients in the rimegepant group, as compared with 12.0% in the placebo group, were free from pain (absolute difference, 7.6 percentage points; 95% confidence interval [CI], 3.3 to 11.9; $P < 0.001$). The percentage of patients who had freedom from their most bothersome symptom 2 hours after the dose was 37.6% in the rimegepant group as compared with 25.2% in the placebo group (absolute difference, 12.4 percentage points; 95% CI, 6.9 to 17.9; $P < 0.001$) (Table 2).

The analyses of the secondary end points, which were tested hierarchically in the order listed in Table 2, showed that freedom from photophobia at 2 hours after the dose was administered was reported in 37.4% in the rimegepant group and in 22.3% in the placebo group




Figure 2. Probability of Freedom from Pain and Freedom from the Most Bothersome Symptom.

The probability of freedom from pain (Panel A) and freedom from the most bothersome symptom other than pain (Panel B) was estimated in an exploratory analysis in the modified intention-to-treat population, which included all patients who underwent randomization, had a migraine attack with pain of moderate or severe intensity, took a dose of rimegepant or placebo, and had at least one efficacy assessment after administration of the dose. Data were censored at the time a patient took rescue medication or 495 minutes after the dose. The reported probabilities are those at the actual time of data collection.

($P < 0.001$), and freedom from phonophobia was reported in 36.7% and 26.8%, respectively ($P = 0.004$). The percentage of patients who had pain relief 2 hours after the dose was 58.1% in the rimegepant group as compared with 42.8% in the placebo group ($P < 0.001$). The percentage of patients who had freedom from nausea 2 hours after the dose did not differ significantly between

Table 3. Adverse Events and Liver-Function Test Findings in the Safety Population.*

Variable	Rimegepant (N=543)	Placebo (N=543)
	<i>number of patients (percent)</i>	
Any adverse event	93 (17.1)	77 (14.2)
Adverse events reported in $\geq 1\%$ of patients in either treatment group		
Nausea	10 (1.8)	6 (1.1)
Urinary tract infection	8 (1.5)	6 (1.1)
Serious adverse event†	1 (0.2)	2 (0.4)
Liver-function tests		
Serum AST or ALT above ULN	13 (2.4)	12 (2.2)
Serum AST or ALT $>3\times$ ULN	0	0
Total bilirubin $>2\times$ ULN	0	0

* The safety population included all patients who underwent randomization and took a dose of rimegepant or placebo. Patients could have had more than one adverse event. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and ULN upper limit of the normal range.

† The serious adverse event reported in the rimegepant group was back pain, and the serious adverse events reported in the placebo group were chest pain (1 patient) and urinary tract infection (1 patient).

the treatment groups (48.1% in the rimegepant group and 43.3% in the placebo group, $P=0.21$). (All percentages are Cochran–Mantel–Haenszel estimates.) As a result of this nonsignificant difference, and in accordance with the hierarchical analysis, no statistical inferences can be drawn from the remainder of the secondary end points. Exploratory analyses of freedom from pain and freedom from the most bothersome symptom during the first 8 hours after the dose of rimegepant or placebo are shown in Figure 2.

SAFETY

The most common adverse events were nausea (1.8% in the rimegepant group and 1.1% in the placebo group) and urinary tract infection (1.5% and 1.1%, respectively). Serious adverse events were reported in one patient in the rimegepant group (back pain) and in two patients in the placebo group (Table 3). Liver-function tests showed serum levels of alanine aminotransferase or aspartate aminotransferase that were above the upper limit of the normal range in 2.4% of the patients who received rimegepant and in 2.2% of the patients who received placebo (Table 3). No patient in either treatment group had an alanine aminotransferase level or an aspartate aminotransferase level of more than three times the upper limit of the normal range, and no total

bilirubin level of more than two times the upper limit of the normal range was observed.

DISCUSSION

A single, oral, 75-mg dose of rimegepant was superior to placebo with respect to the primary end points of freedom from pain and freedom from the patient's most bothersome symptom 2 hours after the dose; pain was eliminated in 19.6% of the patients who received rimegepant, as compared with 12.0% of the patients who received placebo. The results of the analyses of the secondary end points of freedom from photophobia, freedom from phonophobia, and pain relief, each assessed 2 hours after the dose of rimegepant or placebo, showed the superiority of rimegepant over placebo; however, rimegepant was not found to be superior to placebo with respect to freedom from nausea. Nausea and urinary tract infection were the only adverse events reported in more than 1% of the patients in each group.

Our trial had several limitations. First, the trial did not include an active comparator to rimegepant. Second, although the rimegepant and placebo groups were balanced with respect to baseline characteristics and features of the treated migraine attack immediately before ad-

ministration of the dose, the single-attack design (i.e., assessment of treatment effect on a single episode of a condition) does not permit assessment of the consistency of the effects of the drug from attack to attack over time in the same patient. Third, although no evidence of adverse cardiac effects was observed, the trial population was not enriched for patients with cardiovascular disease.

This trial showed that among patients with migraine, treatment of an attack with rimegepant, which acts through inhibition of the CGRP receptor, resulted in a moderately higher percentage of patients who were free from pain and

free from their most bothersome symptom 2 hours after the dose than placebo. Larger and longer trials are needed to determine the consistency of response and the safety and effectiveness of the drug as compared with other migraine treatments.

A data sharing statement provided by the authors is available with the full text of this article at [NEJM.org](https://www.nejm.org).

Supported by Biohaven Pharmaceuticals.

Disclosure forms provided by the authors are available with the full text of this article at [NEJM.org](https://www.nejm.org).

We thank the patients, investigators, and site personnel who participated in the trial; Ashwini Ghatpande, Francine Healy, and Christopher Jensen for the preparation of the clinical study report and for their review of earlier versions of the manuscript; and Christopher Caiazza (with funding from Biohaven Pharmaceuticals) for medical writing support.

REFERENCES

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1211-59.
2. Lipton RB, Munjal S, Buse DC, et al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study. *Headache* 2017;57:1026-40.
3. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. *Drugs* 1998;55:889-922.
4. Cortelli P, Allais G, Tullo V, et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. *Neurol Sci* 2011;32:Suppl 1:S95-S98.
5. Géraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. *Headache* 2003;43:376-88.
6. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. *Cochrane Database Syst Rev* 2012;2:CD008615.
7. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. *Headache* 2003;43:36-43.
8. Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) Study. *Headache* 2017;57:31-44.
9. Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) Study. *Headache* 2017;57:1507-21.
10. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. *Physiol Rev* 2017;97:553-622.
11. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. *Ann Neurol* 1990;28:183-7.
12. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. *Ann Neurol* 1993;33:48-56.
13. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. *Cephalalgia* 2011;31:712-22.
14. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. *Lancet* 2008;372:2115-23.
15. Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. *Cephalalgia* 2011;31:573-84.
16. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. *Cephalalgia* 2014;34:114-25.
17. Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. *Cephalalgia* 2016;36:887-98.
18. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013;33:629-808.
19. Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary results from a multicenter clinical trial in generalized anxiety disorder. *Psychiatry (Edgmont)* 2009;6:26-31.

Copyright © 2019 Massachusetts Medical Society.